DBV Technologies announces first subject screened in COMFORT Toddlers trial

DBV Technologies (DBVT) provided an update on the progress on the company’s COMFORT Toddlers supplemental safety study using the Viaskin Peanut patch 250 microgram in peanut-allergic children ages 1-3 years old. COMFORT Toddlers will enroll approximately 480 subjects at approximately 80-90 study centers across the U.S., Canada, Australia, UK and Europe. Principal Investigator Jeffrey Leflein screened the first subject in the study. Additionally, Allergy and Asthma Center in Maplewood, Minnesota and Hamilton Allergy and Immunology Clinic in Ontario, Canada have been activated and are currently open to recruitment.